FDA advisers warn of more deaths if drug is relaunched.
Moynihan
Ray
R
D002243:Carbolines / Q000009:adverse effects*; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D017277:Drug Approval; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D002243:Carbolines; D005765:Gastrointestinal Agents; C090840:alosetron